Jun 25, 2024

Posted June 25, 2024 Jonathan Bush, founder and CEO of Zus Health, and Chris Severn, cofounder and CEO of Turquoise Health, joined Julie Yoo, general partner, and Colin Rom, head of public policy for a16z Bio + Health. We’ve long believed that regulatory change can be a catalyst for company creation. In this episode, Jonathan and Chris detail how that was true for them. They also outline a few key takeaways for founders hoping to leverage regulatory change themselves. Policy can be shaped—but that often requires relationship-building As Chris and Jonathan both told us during the episode, policymakers often don’t get to hear from technologists and founders; instead, incumbents, like health systems and pharmaceutical companies, are often front and center. But that doesn’t mean policymakers aren’t open to hearing from entrepreneurs. When Chris and his cofounder Adam found an online notice for a public forum with key government agencies during the comment period for what became the Hospital Price Transparency Rule, they reached out to the agencies and asked if they’d be interested in speaking to founders. The agencies agreed, and Chris and Adam got to help shape the eventual rule. Jonathan also shared how he similarly contributed to the shaping of the 21st Century Cures Act. Regulations change over time Even once a law is passed, how that law is interpreted and implemented often evolves as the impacted parties gain more experience and provide feedback to regulators. As Colin points out during the episode, that feedback to policymakers most often stems from the most vocal constituents, which in healthcare are usually the biggest employers in a given district (typically health systems or other large corporations). But they don’t as often hear from founders about how a specific rule might affect innovation or patient care. Being able to explain clearly the downstream effects can make a big difference as the policy continues to be shaped (often a long process!). And again, relationships matter. As Jonathan notes, “One of the things that is interesting about the way Washington works is that when a congressman says, we want to work with industry. A) they mean it, they genuinely do. But B) they mean people who have Washington offices. So basically, they don’t mean 99 percent of the new products and new companies in the world.” This doesn’t mean you have to have a Washington office. But it does mean that you have to build relationships like you do. Policy can have unintended consequences for startups, both good and bad Perhaps the opposite of regulation as a catalyst is regulatory capture. Regulatory capture can be used by incumbents to, as Jonathan puts it on the episode, “close the airlock” behind them. By enacting onerous regulations or requirements, policy can be used to keep smaller, more innovative companies out of the field. Companies should respond by building their relationships in DC, keeping an eye on potential changes that could affect them, and, as Chris says, continually earning their “right to win,” the x-factor that keeps the company ahead of the competition. Which brings us to the last point to highlight… Regulation can be a catalyst…but creating durable businesses requires much more While companies like Turquoise and Zus can take advantage of the opening in the market that is created by a new rule, regulation, or policy, it takes far more to create a differentiated, durable, and scalable business on top of that. Jonathan talks about how companies need to create enough value to fight past the “performative compliance” that incumbents often put on display, in which they do the minimal amount of work to check the box on regulatory compliance. Chris also weighed in on how he was able to turn his product into a competitive advantage for his customers, in addition to helping them comply with the transparency rules. Even though both founders admit that their companies probably wouldn’t exist if not for the relevant rules and regulations, they both recognize that those rules and regs were a necessary but not sufficient justification for them to decide that it was their time to build. Want more a16z Bio + Health? Sign up for our bio + health newsletter to get the latest take from us on the future of biology, technology, and care delivery. Thanks for signing up for the a16z Bio + Health newsletter. Check your inbox for a welcome note. The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/ . Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information. More About This Podcast Biology and the state of healthcare are undergoing radical shifts. Raising Health delves into dialogues with scientists, technologists, founders, builders, leaders, and visionaries as they explore how AI, engineering, and technology elevate health to new heights and create a system of enduring health for all. RECOMMENDED FOR YOU